Pasar al contenido principal

COMPORTAMIENTO E INSTITUCIONES CON APLICACIONES A ECONOMIA DE LA SALUD Y DE LA INNOVACION

ECO2015-63679-P

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Private versus social incentives for pharmaceutical innovation

  • González, Paula|||0000-0003-1630-9726
  • Macho Stadler, Inés|||0000-0002-2415-7972
  • Pérez Castrillo, David|||0000-0002-1840-7621
We provide a theoretical framework to contribute to the current debate regarding the tendency of pharmaceutical companies to direct their R&D toward marketing products that are follow-on drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a model with a population of patients who can be treated with drugs that are horizontally and vertically differentiated. In addition to a pioneering drug, a new drug can be marketed as the result of an innovative process. We analyze physician prescription choices and the optimal pricing decision of an innovative firm. We also characterize the incentives of the innovative firm to conduct R&D activities, disentangling the quest for breakthrough drugs from the firm effort to develop follow-on drugs. Our results offer theoretical support for the conventional wisdom that pharmaceutical firms devote too many resources to conducting R&D activities that lead to incremental innovations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Endogenous matching in university-industry collaboration, theory and empirical evidence from the UK

  • Banal Estañol, Albert
  • Macho Stadler, Inés|||0000-0002-2415-7972
  • Pérez Castrillo, David|||0000-0002-1840-7621
We use a two-sided matching framework to analyze collaboration between heterogeneous academics and firms. We consider both horizontal and vertical characteristics-those related to affinity (e.g., preferences for a type of scientific research) and those related to ability (e.g., capacity to produce high-quality scientific output). We build a unique data set based on the teams of academics and firms that proposed research projects to the UK's Engineering and Physical Sciences Research Council. Our results are suggestive of positive assortative matching in terms of ability and type, while the matching is negative assortative in terms of their interactions. The most able and the most applied academics are the ones that are more likely to propose collaborative as opposed to noncollaborative projects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The outcome of competitive equilibrium rules in buyer-seller markets when the agents play strategically

  • Pérez Castrillo, David|||0000-0002-1840-7621
  • Sotomayor, Marilda A. Oliveira
We analyze the two-stage games induced by competitive equilibrium rules for the buyer-seller market of Shapley and Shubik (Int J Game Theory 1:111-130, 1972). In these procedures, first sellers and then buyers report their valuation and the outcome is determined by a competitive equilibrium outcome for the market reported by the agents. We provide results concerning buyers and sellers' equilibrium strategies. In particular, our results point out that, by playing first, sellers are able to instigate an outcome that corresponds to the sellers' optimal competitive equilibrium allocation for the true market.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Firm size distortions under duopoly, Distorsiones del tamaño empresarial en duopolio

  • González Maestre, Miguel
  • Peñarrubia, Diego
Motivated by the fact that some regulations involve extra costs for those firms at a size beyond a critical threshold, this paper contributes to the analysis of the welfare distortions due to these regulations. In the context of a duopoly, our results show that social welfare is not monotonic with the regulatory threshold. In particular, we obtain the paradoxical result that a policy decision of increasing the threshold might involve a dramatic decrease in welfare in some markets. An interesting consequence of this result is that the positive discrimination towards small firms is a rather subtle issue. Our results suggest that the relevant regulatory thresholds should differ across industries. Apparently, this is taken into account in some countries (e.g., USA), but not in many other countries., Motivado por el hecho de que con frecuencia algunas regulaciones implican un coste extra para las empresas cuyo tamaño supera un cierto umbral, este trabajo analiza los efectos sobre el bienestar de estas regulaciones. En el contexto de un duopolio, nuestros resultados muestran que dichos efectos no son monótonos en el umbral regulatorio. En concreto, obtenemos el resultado paradójico de que la decisión regulatoria de elevar un poco el umbral puede generar reducciones abruptas del bienestar. Una consecuencia interesante de este resultado es que la discriminación positiva hacia las empresas pequeñas es un asunto muy sutil. Los resultados sugieren que los umbrales regulatorios relevantes deben diferir entre sectores. Aparentemente, esto se tiene en cuenta en algunos países (como EE.UU.) pero no en muchos otros.